Supplementary Text from Phase I Safety, Pharmacokinetic and Pharmacodynamic Evaluation of the Vascular Disrupting Agent Ombrabulin (AVE8062) in Patients with Advanced Solid Tumors
Year: 2023
Type: supplementary-materials
Abstract: Supplementary Text - PDF file 76K, DCE methodology and results
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: gold
OpenAlex ID: W4361827439
